NCT04345887View on ClinicalTrials.gov

Spironolactone in Covid-19 Induced ARDS

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

May 5, 2020

Primary Completion Date

June 15, 2020

Study Completion Date

July 5, 2020

Conditions
Respiratory Distress Syndrome, Adult
Interventions
DRUG

Spironolactone 100mg

2x100 mg spironolactone for 5 consecutive days

DRUG

Placebo oral tablet

2 x1 placebo tablet

Trial Locations (1)

Unknown

Istanbul University-Cerrahpaşa, Istanbul

All Listed Sponsors
lead

Istanbul University - Cerrahpasa

OTHER

NCT04345887 - Spironolactone in Covid-19 Induced ARDS | Biotech Hunter | Biotech Hunter